N. Lang

134 Effect of intravenous iron (ferric derisomaltose) on haemoglobin and clinical events according to age in patients with heart failure and iron deficiency in a randomised trial (ironman)
20230 citationsauthor #3
Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial
202321 citationsauthor #18
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Cancer Therapy Trials of Combined Immune Checkpoint and VEGF Inhibitors: A Systematic Review
20230 citationsauthor #9
Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
202333 citationsauthor #10
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity
202330 citationsauthor #3
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials
202311 citationsauthor #7
Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
20238 citationsauthor #4
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
202380 citationsauthor #13
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial
202331 citationsauthor #29
Post-COVID-19 illness and associations with sex and gender
202310 citationsauthor #99
Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
202384 citationsauthor #7
Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19
20231 citationsauthor #20
S-45-3: PARP INHIBITION AMELIORATES VEGF INHIBITOR-ASSOCIATED VASCULAR DYSFUNCTION VIA TRPM2
20230 citationsauthor #3
Cardiotoxicity of BRAF/MEK Inhibitors
202322 citationsauthor #8
#3880 REDUCED EGFR IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH RENAL CANCER WHO RECEIVED TARGETED SYSTEMIC ANTI-CANCER THERAPY
20230 citationsauthor #3
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort
202221 citationsauthor #7
Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort
202290 citationsauthor #9
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction
202243 citationsauthor #11
Runx1 deficiency protects against heart failure with preserved ejection fraction
20220 citationsauthor #5
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes
20228 citationsauthor #6
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
20229 citationsauthor #17
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
2022228 citationsauthor #14
Abstract 12418: Prevalence and Clinical Characteristics of Patients With Decompensated Heart Failure and Clonal Haematopoiesis of Indeterminate Potential
20220 citationsauthor #10
Long-term cardiovascular outcomes in five-year cancer survivors: a nationwide cohort study
20221 citationsauthor #3
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes
202213 citationsauthor #4
A multisystem, cardio-renal investigation of post-COVID-19 illness
202261 citationsauthor #19
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
20228 citationsauthor #20
Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients
202225 citationsauthor #5
157 Multi-system investigation of covid-19 illness
20220 citationsauthor #13
Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies
202235 citationsauthor #4
Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease
20223 citationsauthor #5
Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review
20228 citationsauthor #4
Rationale and design of a randomised trial of intravenous iron in patients with heart failure
202211 citationsauthor #7
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors
202259 citationsauthor #7
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-98623 1 ) in chronic heart failure: a randomized trial
20212 citationsauthor #1
Post-COVID-19 illness trajectory: a multisystem investigation.
20210 citationsauthor #20
Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland
20212 citationsauthor #6
Reply
20210 citationsauthor #5
Haemodynamic effects of the nitroxyl donor cimlanod (BMS‐986231) in chronic heart failure: a randomized trial
202120 citationsauthor #1
Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure
202120 citationsauthor #7
Cardiovascular Oncologic Emergencies
20210 citationsauthor #9
Effect of hypoglycaemia on measures of myocardial blood flow and myocardial injury in adults with and without type 1 diabetes: A prospective, randomised, open‐label, blinded endpoint, cross‐over study
20210 citationsauthor #3
Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity
20213 citationsauthor #1
Interleukin-6 and outcomes in patients recently hospitalized with heart failure and preserved ejection fraction
20211 citationsauthor #8
Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
202183 citationsauthor #9
Abstract 44: VEGF Inhibitor-induced Vascular Dysfunction Is Ameliorated By PARP/TRPM2 Inhibition
20210 citationsauthor #3
Cardiotoxic effects of angiogenesis inhibitors
202169 citationsauthor #5
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
2021131 citationsauthor #17
Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study
202149 citationsauthor #9
The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study
202036 citationsauthor #13
Cardiotoxicity and myocardial hypoperfusion associated with anti‐vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer
202018 citationsauthor #12
Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer
202028 citationsauthor #12
Vascular toxicity associated with anti-angiogenic drugs.
202048 citationsauthor #3
Effect of Hypoglycemia on Measures of Myocardial Blood Flow and Myocardial Injury in Adults With and Without Type 1 Diabetes: A Prospective, Randomized, Open-Label, Blinded Endpoint, Cross-Over Study
20200 citationsauthor #3
Abstract P1-13-02: Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data
20200 citationsauthor #11
HEMODYNAMIC EFFECTS OF NITROXYL DONOR BMS-986231 COMPARED TO NITROGLYCERIN OR PLACEBO IN PATIENTS WITH CHRONIC HEART FAILURE-A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL
20200 citationsauthor #7
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
2020313 citationsauthor #13
Abnormalities of the lymphatic system and impaired fluid clearance in patients with heart failure with preserved ejection fraction
20200 citationsauthor #7
MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE MARKERS OF ANGIOGENESIS INHIBITOR-INDUCED CARDIOTOXICITY
20200 citationsauthor #13
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study.
202024 citationsauthor #15
EMPEROR-REDUCED reigns while EMPERIAL whimpers.
20207 citationsauthor #3
Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction
202060 citationsauthor #7
Hypertension and Antiangiogenesis
20195 citationsauthor #2
Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction.
20192 citationsauthor #2
Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it
20198 citationsauthor #4
Cisplatin related cardiotoxicity – acute and chronic cardiovascular morbidity in a testicular cancer survivor
20196 citationsauthor #5
Prehypertension and Cardiometabolic Syndrome
20193 citationsauthor #70
Vascular Biology of Cancer Chemotherapeutic Drugs
20190 citationsauthor #3
Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation
20194 citationsauthor #6
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors
201858 citationsauthor #6
VASCULAR EFFECTS OF ANTI-CANCER CISPLATIN THERAPY
20181 citationsauthor #7
Antihypertensive Drugs and Vascular Health
20180 citationsauthor #3
Adult Congenital Heart Disease and Radiation Exposure: The Malignant Price of Cardiac Care
20187 citationsauthor #1
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF
201740 citationsauthor #5
Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus
201734 citationsauthor #6
Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus
201632 citationsauthor #9
Chapter 10 – Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors
20160 citationsauthor #2
Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure
201631 citationsauthor #6
Drug Treatment of Hypertension: Focus on Vascular Health
201662 citationsauthor #2
Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury.
201616 citationsauthor #11
Vascular Complications of Cancer Chemotherapy
2016199 citationsauthor #3
The ease of use and reproducibility of the Alere™ Heart Check System: a comparison of patient and healthcare professional measurement of BNP.
201412 citationsauthor #1
Biomarkers of acute rejection following cardiac transplantation.
201412 citationsauthor #2
Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy.
20142 citationsauthor #1
Emerging biomarkers for heart failure: an update.
20145 citationsauthor #4
UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase.
2014264 citationsauthor #4
Heart failure resistant to standard medical therapy
20140 citationsauthor #2
UVA lowers blood pressure and vasodilates the systemic arterial vasculature by mobilisation of cutaneous nitric oxide stores
20132 citationsauthor #3
Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans
201332 citationsauthor #4
912Nanoparticle Enhanced CMR – A Novel Method Of Investigating Myocardial Inflammation & Dysfunction
20130 citationsauthor #6
Quantitative myocardial inflammation assessed using a novel USPIO-Magnetic Resonance Imaging acquisition and analysis protocol
20133 citationsauthor #8
NANOPARTICLE ENHANCED MRI: A NOVEL METHOD OF INVESTIGATING MYOCARDIAL INFLAMMATION
20131 citationsauthor #6
Cardiology Symposium 2012 Report held on 15 November at the Royal College of Physicians of Edinburgh
20130 citationsauthor #1
Role of Asymmetric Methylarginine and Connexin 43 in the Regulation of Pulmonary Endothelial Function
201327 citationsauthor #10
EFFECT OF UROCORTIN 2 AND 3 ON FOREARM ARTERIAL BLOOD FLOW IN PATIENTS WITH HEART FAILURE
20131 citationsauthor #4
Abstract 11360: Augmentation of Connexin-43 Conductance Reduces Ischemia-Reperfusion Injury and Myocardial Infarct Size
20120 citationsauthor #2
Cardiac compression causing fatal acute ST-segment elevation myocardial infarction.
20123 citationsauthor #1
Augmentation of Connexin-43 Conductance Reduces Isehemia-Reperfusion Injury and Myocardial Infarct Size
20121 citationsauthor #2
IN VIVO ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION
20120 citationsauthor #5
The role of ADMA in the regulation of pulmonary endothelial cell-to-cell communication, endothelial permeability and angiogenesis
20120 citationsauthor #4

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT